Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir/lamivudine - GSK

Next Previous
Drug Profile

Dolutegravir/lamivudine - GSK

Alternative Names: Dovato; DTG/3TC; Lamivudine/dolutegravir

Latest Information Update: 07 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK; ViiV Healthcare
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Oxazines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections
  • Phase III HIV infections

Most Recent Events

  • 27 Jul 2026 Efficacy and adverse event data from the phase IIIb VOGUE trial in HIV-1 infections released by ViiV Healthcare
  • 20 Apr 2026 ViiV Healthcare in collaboration with GlaxoSmithKline and PPD completes a phase IIIb VOLITION trial for HIV-1 infections (Treatment-naïve) in USA, Canada, Puerto Rico, France, Argentina, Germany, Chile, Italy, and Spain(PO) (NCT05917509)
  • 09 Feb 2026 ViiV Healthcare completes a phase-III clinical trials in HIV infections (Treatment-experienced) in Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Mexico, Portugal, Spain, United Kingdom, USA (PO) (NCT05911360)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top